These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
397 related articles for article (PubMed ID: 10589763)
41. Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Imbeaud S; Faure E; Lamarre I; Mattéi MG; di Clemente N; Tizard R; Carré-Eusèbe D; Belville C; Tragethon L; Tonkin C; Nelson J; McAuliffe M; Bidart JM; Lababidi A; Josso N; Cate RL; Picard JY Nat Genet; 1995 Dec; 11(4):382-8. PubMed ID: 7493017 [TBL] [Abstract][Full Text] [Related]
42. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia. Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576 [TBL] [Abstract][Full Text] [Related]
55. [Study on the anti-müllerian hormone served as a marker for granulosa cell tumor of ovary]. Long W; Wang W; Rey R Zhonghua Fu Chan Ke Za Zhi; 2000 Jun; 35(6):356-8. PubMed ID: 11776178 [TBL] [Abstract][Full Text] [Related]
56. Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. Fuller AF; Guy S; Budzik GP; Donahoe PK J Clin Endocrinol Metab; 1982 May; 54(5):1051-5. PubMed ID: 6895900 [TBL] [Abstract][Full Text] [Related]
57. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo. Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638 [TBL] [Abstract][Full Text] [Related]
58. Anti-Müllerian hormone is a specific marker of sertoli- and granulosa-cell origin in gonadal tumors. Rey R; Sabourin JC; Venara M; Long WQ; Jaubert F; Zeller WP; Duvillard P; Chemes H; Bidart JM Hum Pathol; 2000 Oct; 31(10):1202-8. PubMed ID: 11070112 [TBL] [Abstract][Full Text] [Related]
59. Patterns of Müllerian Inhibiting Substance Type II and Candidate Type I Receptors in Epithelial Ovarian Cancer. Basal E; Ayeni T; Zhang Q; Langstraat C; Donahoe PK; Pepin D; Yin X; Leof E; Cliby W Curr Mol Med; 2016; 16(3):222-31. PubMed ID: 26917267 [TBL] [Abstract][Full Text] [Related]
60. Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the rat. Tsuji M; Shima H; Yonemura CY; Brody J; Donahoe PK; Cunha GR Endocrinology; 1992 Sep; 131(3):1481-8. PubMed ID: 1505479 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]